In contrast to previous studies, we found an increased incidence of hypophysitis with anti‐PD1/anti‐PDL1 and a rarity of primary thyroid dysfunction with anti‐CTLA4 treatment, which could be attributed to genetic/ethnic variations. The gene discussed is CTLA4; the disease is hypophysitis.